drugset / Trial / NCT03126812
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm feasibility study in patients with primary FIGO stage IV serous ovarian, peritoneal, or fallopian tube cancer to evaluate neo-adjuvant + adjuvant pembrolizumab for its capacity to induce and broaden T cell responses against tumor neo-antigens.
Timeline
- Start
- 2017-11-01
- Primary completion
- 2023-06-01
- Completion
- 2024-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |